Neuronetics (STIM) News Today → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Free STIM Stock Alerts $3.52 -0.23 (-6.13%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineNeuronetics Announces Q1 2024 Earnings Release and Conference Callmsn.com - April 25 at 12:04 PMNeuronetics to Report First Quarter 2024 Financial and Operating Results and Host Conference Callglobenewswire.com - April 23 at 4:30 PMShort Interest in Neuronetics, Inc. (NASDAQ:STIM) Rises By 77.8%marketbeat.com - April 12 at 3:58 PMNew Study Offers Hope for Depression Patients Undergoing TMS Therapymsn.com - April 12 at 1:57 AMNew Publication in Brain Stimulation Confirms Full TMS Treatment Course Is Vitalglobenewswire.com - April 10 at 8:31 AMKent Lake Capital LLC Has $3.24 Million Stake in Neuronetics, Inc. (NASDAQ:STIM)marketbeat.com - April 6 at 7:36 PMNeuronetics Stock (NASDAQ:STIM), Quotes and News Summarybenzinga.com - April 5 at 5:38 AMNeuronetics Bolsters Talent Pool with Strategic Stock Incentives for New Hiresmsn.com - April 1 at 1:05 AMFDA Clears NeuroStar's TMS Therapy for Adolescents with Major Depressive Disordermsn.com - March 29 at 12:15 AMNeuronetics, Inc. (NASDAQ:STIM) Short Interest Updatemarketbeat.com - March 28 at 11:57 AMNeuronetics wins FDA clearance for device to treat adolescents with depressionfinance.yahoo.com - March 27 at 4:43 PMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - March 27 at 4:43 PMNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 27 at 4:30 PMBuy Rating for Neuronetics Amid FDA Clearance and Expanding Adolescent MDD Marketmarkets.businessinsider.com - March 27 at 6:41 AMNeuronetics' (STIM) "Market Perform" Rating Reiterated at William Blairmarketbeat.com - March 26 at 3:29 PMNeuronetics’s NeuroStar wins FDA clearance for adolescents with depressionmsn.com - March 25 at 10:48 PMNeuronetics: NeuroStar Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depressionfinanznachrichten.de - March 25 at 12:07 PMNeuronetics Shares Climb 15% After FDA Cleared Depression Treatment for Adolescents Aged 15 to 21marketwatch.com - March 25 at 12:07 PMNeuronetics: NeuroStar Advanced Therapy Gets FDA Clearance For New Indicationmarkets.businessinsider.com - March 25 at 12:07 PMNeuroStar® Advanced Therapy Receives FDA Clearance as a First-Line Add-On Treatment for Adolescents with Depressionglobenewswire.com - March 25 at 8:30 AMSTIM Apr 2024 5.000 putfinance.yahoo.com - March 16 at 8:16 AMNeuronetics and Transformations Care Network Join Forces to Expand Availability of Innovative Depression Treatmentmsn.com - March 12 at 10:47 AMNeuronetics, Inc. (STIM) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 7 at 6:45 PMNeuronetics Inc (STIM) Reports Record Revenues in Q4 and Full Year 2023finance.yahoo.com - March 7 at 6:45 PMNeuronetics, Inc. (NASDAQ:STIM) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - March 7 at 1:03 PMNeuronetics Announces 5-Year Exclusive Partnership with Transformations Care Networkglobenewswire.com - March 7 at 8:22 AMNeuronetics GAAP EPS of -$0.19 beats by $0.07, revenue of $20.31M beats by $0.31Mmsn.com - March 6 at 5:02 PMNeuronetics Full Year 2023 Earnings: US$1.05 loss per share (vs US$1.38 loss in FY 2022)finance.yahoo.com - March 6 at 5:02 PMPiper Sandler Reiterates Overweight Rating for Neuronetics (NASDAQ:STIM)marketbeat.com - March 6 at 9:45 AMNeuronetics (NASDAQ:STIM) Posts Quarterly Earnings Results, Beats Estimates By $0.07 EPSmarketbeat.com - March 6 at 9:30 AMNeuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Resultsfinance.yahoo.com - March 5 at 7:38 AMNeuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Resultsglobenewswire.com - March 5 at 7:30 AMNeuronetics Q4 2023 Earnings Previewmsn.com - March 4 at 5:28 PMWilliam Andrew Macan Sells 22,377 Shares of Neuronetics, Inc. (NASDAQ:STIM) Stockmarketbeat.com - March 1 at 7:12 PMNeuronetics (STIM) Set to Announce Quarterly Earnings on Tuesdaymarketbeat.com - February 27 at 5:08 AMNeuronetics Set to Announce Q4 2023 Financial Results, Highlights Advances in Mental Health Treatmentmsn.com - February 22 at 10:53 AMNeuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Callfinance.yahoo.com - February 20 at 9:28 AMNeuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Callglobenewswire.com - February 20 at 8:30 AMNeuronetics, Inc. (NASDAQ:STIM) EVP William Andrew Macan Sells 15,621 Sharesmarketbeat.com - February 16 at 7:27 PMNeuronetics Revamps TrakStar System, Streamlining Patient Data Managementmsn.com - February 14 at 10:07 AMNeuronetics Launches Latest Evolution in its TrakStar® Patient Data Management Systemfinance.yahoo.com - February 12 at 8:59 AMDepression Treatment Access Expanded By Lucet Health Policy Changemsn.com - February 8 at 8:56 AMFirst Eagle Investment Management LLC Purchases 195,834 Shares of Neuronetics, Inc. (NASDAQ:STIM)marketbeat.com - February 8 at 8:16 AMNeuroStar TMS Patient Access Expands Through Lucet Health Policy Updatefinance.yahoo.com - February 6 at 9:34 AMAllspring Global Investments Holdings LLC Sells 160,730 Shares of Neuronetics, Inc. (NASDAQ:STIM)marketbeat.com - February 2 at 4:38 AMNeuronetics: Modest Improvements Are Not Enoughseekingalpha.com - January 30 at 7:31 AMAfter losing 41% in the past year, Neuronetics, Inc. (NASDAQ:STIM) institutional owners must be relieved by the recent gainfinance.yahoo.com - January 23 at 8:44 AMBrainsWay launches feasibility studies to test rotational field TMSmsn.com - January 11 at 8:49 PMNeuronetics Stock Receives Buy Rating from Canaccord Genuity Amid Strong Q4 Performance and Positive Outlookmarkets.businessinsider.com - January 10 at 8:27 AMNeuronetics, Inc. (STIM) interactive stock chart – Yahoo Financeuk.finance.yahoo.com - January 9 at 10:07 AM Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address It’s now possible to know the win rate of every trade… BEFORE you take it! (Ad)Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << STIM Media Mentions By Week STIM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. STIM News Sentiment▼0.000.41▲Average Medical News Sentiment STIM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. STIM Articles This Week▼31▲STIM Articles Average Week Get Neuronetics News Delivered to You Automatically Sign up to receive the latest news and ratings for STIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TELA News Today KRMD News Today BLUA News Today DCTH News Today ALUR News Today CLPT News Today BWAY News Today NVNO News Today MGRM News Today OBIO News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:STIM) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuronetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
